Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Consensus Target Price of $18.75 According to Analysts

Posted by Brenda Bartman on Sep 25th, 2026

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS – Get Free Report) have been given an average rating of “Moderate Buy” by the seven research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $18.75.

A number of research analysts have commented on the company. TD Cowen began coverage on Kalaris Therapeutics in a report on Monday, June 15th. They set a “buy” rating on the stock. Weiss Ratings downgraded Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Finally, Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 13th.

Check Out Our Latest Analysis on Kalaris Therapeutics

Kalaris Therapeutics Price Performance

Shares of KLRS stock opened at $3.07 on Friday. The firm has a fifty day moving average of $3.78 and a two-hundred day moving average of $4.91. The firm has a market cap of $73.10 million, a P/E ratio of -1.52 and a beta of 0.22. Kalaris Therapeutics has a 1-year low of $3.02 and a 1-year high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. On average, sell-side analysts expect that Kalaris Therapeutics will post -1.99 EPS for the current year.

Institutional Trading of Kalaris Therapeutics

Several institutional investors have recently added to or reduced their stakes in KLRS. Pale Fire Capital SE bought a new position in shares of Kalaris Therapeutics in the 2nd quarter worth about $161,000. Sigma Planning Corp acquired a new stake in Kalaris Therapeutics during the second quarter worth about $41,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Kalaris Therapeutics in the second quarter worth about $122,000. BlackRock Inc. bought a new position in Kalaris Therapeutics in the second quarter worth about $222,000. Finally, Velan Capital Investment Management LP boosted its stake in Kalaris Therapeutics by 38.9% in the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after acquiring an additional 7,000 shares during the period. Institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

(Get Free Report)

Kalaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases and other serious eye disorders. Its research programs are aimed at addressing diseases in which abnormal blood-vessel growth or leakage can impair vision.

The company’s activities include the discovery and clinical development of investigational ophthalmic medicines intended to improve outcomes for patients with retinal conditions. Kalaris Therapeutics has not yet established a broad portfolio of marketed products, and its principal programs remain in development.

Publicly available information about the company’s broader operating history, geographic reach and leadership is limited.